Flow cytometric analysis to predict prognosis in children with chronic-phase CML treated with imatinib

2017 Fiscal Year Final Research Report

• Project/Area Number: 26461594
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Pediatrics
• Research Institution: Keio University
• Principal Investigator: Shima Haruko 慶應義塾大学, 医学部(信濃町), 助教 (80424167)
• Co-Investigator(Kenkyū-buntansha): 嶋田 博之 慶應義塾大学, 医学部(信濃町), 講師 (80265868)
• Co-Investigator(Renkei-kenkyūsha): KIYOKAWA Nobutaka 国立研究開発法人国立成育医療研究センター, 小児血液・腫瘍研究部, 部長 (60195401)
• Project Period (FY): 2014-04-01 – 2018-03-31
• Keywords: 小児慢性骨髄性白血病 / フローサイトメトリー / チロシンキナーゼ阻害剤

Outline of Final Research Achievements

Chronic myeloid leukemia (CML) is a clonal myeloproliferative disorder of hematopoietic stem cells (HSCs). This study aimed to investigate novel prognostic factor of CML using flow cytometry. Bone marrow samples of newly diagnosed children with chronic-phase CML were obtained at diagnosis and after imatinib initiation and stained with anti-human CD34, CD38, CD123, CD45RA, cMpl, and lineage antibodies. Flow cytometric analysis revealed that granulocyte macrophage progenitor predominance in CML progenitors at diagnosis and cMpl elevated expression in bone marrow progenitors at 3 months may predict poor outcome in children with chronic-phase CML treated with imatinib. We recommend flow cytometric analysis of bone marrow in the early phase of treatment, as it is a convenient tool that may predict treatment response and CML management.

Free Research Field

小児血液腫瘍